Youli Li

Dr. Youli Li

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Blood Research
Verified
Journal Article
Open access
PDF file
YLYouli Li
Youli Li
YWYonghe Wu
Yonghe Wu
SCSufen Cao
Sufen Cao
BYBaohua Yu
Baohua Yu
QZQunling Zhang
Qunling Zhang
GCGuangliang Chen
Guangliang Chen
Background: Immunochemotherapy has demonstrated a promising efficacy for a variety of B-cell lymphoma but has limited efficacy for Epstein–Barr virus-positive (EBV +) diffuse large B-cell lymphoma (DLBCL) that is refractory or relapsed to conventional chemotherapy regimens. Considering higher programmed death-ligand 1 (PD-L1) expression in the subset of patients with DLBCL with positive EBV, we speculated that PD-1 inhibitors plus chemotherapy may be an alternative regimen in patients with refractory/relapsed EBV + DLBCL. Methods: This retrospective study included six adult patients diagnosed with refractory EBV + DLBCL resistant to first-line immunochemotherapy regimens (R-CHOP). These patients received PD-1 inhibitors plus chemotherapy as second-line treatment. Results: The final analysis included six patients (four men and two women (median age, 50 years; range, 39–83 years)). Four patients were diagnosed with Epstein–Barr virus (EBV) + DLBCL, and two had DLBCL associated with chronic inflammation. Over a median follow-up of 20 months (range, 2–31 months), the objective response rate was 83% (5/6) and the complete remission rate was 67% (4/6). No severe immune-related adverse reactions occurred, and only a mild rash was reported, which did not necessitate the discontinuation of therapy. Conclusion: The combination of PD-1 inhibitors and chemotherapy offers promising results as a second-line treatment for patients with refractory EBV + DLBCL that is resistant to first-line immunochemotherapy regimens. These preliminary findings warrant further investigation in larger clinical trials to validate the efficacy and safety of this therapeutic approach.

24 January 2026 in Cancer Biome and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YLYouli Li
Youli Li
YCYang Chen
Yang Chen
YMYuxin Mu
Yuxin Mu
XXXuemei Xiu
Xuemei Xiu
WQWenxing Qin
Wenxing Qin
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer with high recurrence and early metastasis. Unlike hormone receptor-positive or HER2-positive cancers, TNBC lacks targeted therapies, and standard chemotherapy often yields limited and transient responses, making treatment challenging. The tumor microenvironment (TME) plays a central role in TNBC progression, immune evasion, and therapy resistance. It comprises multiple cellular components, tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), tumor-infiltrating lymphocytes (TILs), and myeloid-derived suppressor cells (MDSCs), as well as structural and signaling elements such as the extracellular matrix (ECM), growth factors, and cytokines. Interactions among these components create an immunosuppressive, pro-tumorigenic milieu that supports cancer cell survival, invasion, and metastasis. Targeting the TME has emerged as a promising therapeutic strategy. Immunotherapies, particularly immune checkpoint inhibitors (ICIs), can restore antitumor immunity by reversing T cell exhaustion and mitigating immune suppression. Response rates remain variable, leading to the exploration of combination approaches that pair ICIs with chemotherapy, radiotherapy, or TME-modulating agents to enhance efficacy. Direct targeting of TME components, including CAFs, TAMs, MDSCs, and ECM remodeling enzymes, is also being developed to disrupt the supportive tumor niche and enhance drug delivery. This review provides a comprehensive overview of the TNBC TME, emphasizing its role in tumor progression and therapy resistance, and summarizes current and emerging strategies to target the TME. By clarifying complex cellular and molecular interactions, these approaches aim to sensitize tumors to therapy, prevent metastasis, and support the development of more effective, personalized treatments for TNBC.